Compare HOFT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | EQ |
|---|---|---|
| Founded | 1924 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 129.0M |
| IPO Year | 1999 | 2018 |
| Metric | HOFT | EQ |
|---|---|---|
| Price | $16.80 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 101.7K | ★ 876.2K |
| Earning Date | 04-16-2026 | 05-25-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $278,139,000.00 | $41,095,000.00 |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $176.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.62 | $0.29 |
| 52 Week High | $18.09 | $3.54 |
| Indicator | HOFT | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 52.86 |
| Support Level | $11.99 | $1.68 |
| Resistance Level | $17.65 | $3.15 |
| Average True Range (ATR) | 1.06 | 0.26 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 59.38 | 26.41 |
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.